What is GlycoMimetics Debt-to-Equity?
GlycoMimetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.74 Mil. GlycoMimetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.07 Mil. GlycoMimetics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $38.41 Mil.
GlycoMimetics's debt to equity for the quarter that ended in Dec. 2023 was 0.02.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for GlycoMimetics's Debt-to-Equity or its related term are showing as below:
GLYC'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.02 Max: 0.02
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of GlycoMimetics was 0.02. The lowest was 0.02. And the median was 0.02.
GlycoMimetics Debt-to-Equity Historical Data
The historical data trend for GlycoMimetics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoMimetics Debt-to-Equity Chart
|
GlycoMimetics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
|
GlycoMimetics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.02 |
0.01 |
0.02 |
0.02 |
0.02 |
Competitive Comparison of GlycoMimetics's Debt-to-Equity
For the Biotechnology subindustry, GlycoMimetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoMimetics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoMimetics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where GlycoMimetics's Debt-to-Equity falls into.
GlycoMimetics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
GlycoMimetics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
GlycoMimetics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoMimetics (GlycoMimetics) Business Description
Traded in Other Exchanges
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
Executives
| Edwin Rock |
officer: Chief Medical Officer |
9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
| Brian M. Hahn |
officer: CFO |
C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
| Daniel M Junius |
director |
C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451 |
| Bruce S Johnson |
officer: SVP & Chief Commercial Officer |
9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850 |
| Chinmaya Rath |
officer: SVP and Chief Business Officer |
9708 MEDICAL CENTER DR., ROCKVILLE MD 20850 |
| Invus Public Equities, L.p. |
10 percent owner |
C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
| Invus Public Equities Advisors, Llc |
10 percent owner |
C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
| Artal Group S.a. |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| Artal International S.c.a. |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| S.a. Westend |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| Administratiekantoor Westend Stichting |
10 percent owner |
CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD |
| Artal International Management S.a. |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661 |
| Amaury Wittouck |
10 percent owner |
VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661 |
| Scott D Sandell |
10 percent owner |
|
| Harout Semerjian |
director, officer: Chief Executive Officer |
300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950 |
GlycoMimetics (GlycoMimetics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GLYC has been successfully added to your